UnitedHealth schedules Q3 results and UnitedHealth Group stock gains 2.80 percent

Published on 10/13/2026 at 11:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q3 consensus is USD 4.12 adjusted earnings per share. UnitedHealth Group stock is EUR 345.20 on October 13, 2026 versus EUR 335.80.

Key points in brief

UnitedHealth Group scheduled its third-quarter 2026 results for October 13, 2026, before the U.S. market open.
Analysts expected adjusted earnings per share of USD 4.12 and revenue of USD 111.38 billion for the third quarter.
The second quarter produced USD 112.03 billion in revenue and USD 6.38 adjusted earnings per share.
UnitedHealth Group stock was at EUR 345.20 at Lang & Schwarz, 2.80 percent above the Xetra close of EUR 335.80.

Isometrische 3D-Illustration eines Healthcare-Netzwerks mit Krankenhaus, Apotheke und Datenzentrum — UnitedHealth Group US91324P1021 als isometrisches 3D-Netzwerk aus Krankenhaus Apotheke Heim und Datenzentrum, Illustration mit AI erstellt.

UnitedHealth Group stock (ISIN US91324P1021) was trading at EUR 345.20 at Lang & Schwarz on October 13, 2026 at 11:20 a.m. CEST, up 2.80 percent versus the Xetra close of EUR 335.80 on October 12, 2026. UnitedHealth Group had scheduled its third-quarter 2026 results for before the U.S. market open on October 13, with the conference call set for 8:00 a.m. ET.

Three dated earnings markers

On July 16, 2026, UnitedHealth Group reported USD 112.03 billion in second-quarter revenue and adjusted earnings per share of USD 6.38, according to Investing.com. On September 15, 2026, the company announced an October 13 release date and an 8:00 a.m. ET call in its release. On October 13, 2026, Investing.com cited consensus for USD 4.12 adjusted earnings per share and USD 111.38 billion in revenue.

What does the margin tell investors

The expected third-quarter figures imply adjusted earnings growth of 41.10 percent from USD 2.92 per share in the year-ago quarter, while revenue is projected to decline 1.60 percent from USD 113.20 billion. That split makes medical-cost control more important than sales growth in the immediate earnings assessment.

UnitedHealth reported a medical care ratio of 86.70 percent in the second quarter, down from 89.40 percent a year earlier, but the result included USD 860.00 million of favorable prior-period medical reserve development. Full-year 2026 adjusted earnings guidance stood at USD 19.50-20.00 per share, according to Yahoo Finance.

Analyst views also set a demanding context. TD Cowen analyst Ryan Langston maintained a Hold rating and cut his target to USD 402.00 from USD 430.00, while Piper Sandler analyst Jessica Tassan reiterated Buy, according to Yahoo Finance. The competing views center on whether stronger Optum performance can offset pressure from Medicare Advantage star ratings and a projected USD 1.50 billion revenue headwind in 2028.

Dates that shape the next move

UnitedHealth Group scheduled the third-quarter results for October 13, 2026, before the market open, with the call at 8:00 a.m. ET. The company said the webcast replay would remain available through October 27, 2026.

Stock advances above Xetra close

At Lang & Schwarz, UnitedHealth Group stock was trading at EUR 345.20 on October 13, 2026 at 11:20 a.m. CEST, up EUR 9.40 or 2.80 percent versus the Xetra close of EUR 335.80 on October 12, 2026. The Xetra listing showed a 52-week range of EUR 222.70 to EUR 400.60 as of October 13, 2026, placing the current euro quote below the yearly high while leaving earnings guidance and medical costs as the immediate fundamental tests. The further course of trading is shown by the continuously updated real-time quote of UnitedHealth Group stock.